ApoptosisInduction Effects of Octreotide on Human Gastric Cancer Cells_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

Department of Surgery, Dalian Friendship Hospital, Dalian 116001， China;

Corresponding author：

Keywords：

OctreotideCell apoptosisGastric cancerSGC7901 cell

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectiveTo study the effects and mechanism of Octreotide to inhibit the proliferation of human gastric cancer cells in vitro. MethodsHuman gastric cancer cell line SGC7901 was treated with Octreotide. Human fibroblast cell line HF and 5FU were used as control. MTT assay and fluorescent microscopy as well as flow cytometry were performed in this study. ResultsOctreotide inhibited the growth of SGC7901 in vitro within certain concentrations. The suppression was quantity dependent but did not occur when up to a certain concentration. There was no difference between Octreotide and 5FU in their inhibition on SGC7901. Octreotide had no effects on normal human fibroblast cell line HF. When SGC7901 was treated with Octreotide, the typical apoptotic bodies were identified by flow cytometry and fluorescent microscopy. ConclusionOctreotide can inhibit the proliferation of human gastric cancer cell line SGC7901 in vitro. The induction of apoptosis by Octreotide might be the primary mechanism.

Citation： L Wencai,GENG Xiaoping,MENG Xiangling,TAN Wenxiang. ApoptosisInduction Effects of Octreotide on Human Gastric Cancer Cells. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2004, 11(3): 238-241. doi: Copy

1.	Goldberg RM, Moertel CG, Wieand HS, et al. A phase Ⅲ evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic [Ｊ]. Cancer, 1995; 76(6)∶ 961.
2.	Tomassetti P, Migliori M, Gullo L. Slowrelease lanreotide treatment in endocrine gastrointestinal tumors [Ｊ]. Am J Gastroenterol， 1998; 93(9)∶1468.
3.	Eriksson B, Renstrup J, Imam H, et al. Highdose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects [Ｊ]. Ann Oncol， 1997; 8(10)∶1041.
4.	Madeira I, Ruszniewski P. Digestive system carcinoid tumors: treatment [Ｊ]. Rev Med Interne， 1999; 20(5)∶421.
5.	郑永唐，贲昆龙. 测定细胞存活和增殖的MTT方法的建立 [Ｊ]. 免疫学杂志， 1992； 8（4）∶266.
6.	Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours [Ｊ]. Gut， 1996; 38(3)∶430.
7.	Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors [Ｊ]. Digestion， 1999; 60（Suppl 2）∶9.
8.	鄂征主编. 组织培养和分子细胞学技术 [M]. 第1版. 北京：北京出版社， 1995∶203～205.
9.	Di Leo A, Bajetta E, Ferrari L, et al. A dosefinding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma [Ｊ]. Cancer, 1996; 78(1)∶35.
10.	Janson ET, Stridsberg M, Gobl A, et al. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies [Ｊ]. Cancer Res, 1998; 58(11)∶2375.
11.	Qin Y, Ertl T, Groot K, et al. Somatostatin analog RC160 inhibits growth of CFPAC1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate [Ｊ]. Int J Cancer, 1995; 60(5)∶694.
12.	Reisine T. Somatostatin receptors [Ｊ]. Am J Physiol， 1995; 269(6 Pt 1)∶G813.
13.	吴苏冬，刘长利，王慧川，等. 参臼胶囊诱导肝癌SMMC7721细胞凋亡 [Ｊ]. 世界华人消化杂志， 2003； 11（7）∶908.

1. Goldberg RM, Moertel CG, Wieand HS, et al. A phase Ⅲ evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic [Ｊ]. Cancer, 1995; 76(6)∶ 961.
2. Tomassetti P, Migliori M, Gullo L. Slowrelease lanreotide treatment in endocrine gastrointestinal tumors [Ｊ]. Am J Gastroenterol， 1998; 93(9)∶1468.
3. Eriksson B, Renstrup J, Imam H, et al. Highdose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects [Ｊ]. Ann Oncol， 1997; 8(10)∶1041.
4. Madeira I, Ruszniewski P. Digestive system carcinoid tumors: treatment [Ｊ]. Rev Med Interne， 1999; 20(5)∶421.
5. 郑永唐，贲昆龙. 测定细胞存活和增殖的MTT方法的建立 [Ｊ]. 免疫学杂志， 1992； 8（4）∶266.
6. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours [Ｊ]. Gut， 1996; 38(3)∶430.
7. Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors [Ｊ]. Digestion， 1999; 60（Suppl 2）∶9.
8. 鄂征主编. 组织培养和分子细胞学技术 [M]. 第1版. 北京：北京出版社， 1995∶203～205.
9. Di Leo A, Bajetta E, Ferrari L, et al. A dosefinding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma [Ｊ]. Cancer, 1996; 78(1)∶35.
10. Janson ET, Stridsberg M, Gobl A, et al. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies [Ｊ]. Cancer Res, 1998; 58(11)∶2375.
11. Qin Y, Ertl T, Groot K, et al. Somatostatin analog RC160 inhibits growth of CFPAC1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate [Ｊ]. Int J Cancer, 1995; 60(5)∶694.
12. Reisine T. Somatostatin receptors [Ｊ]. Am J Physiol， 1995; 269(6 Pt 1)∶G813.
13. 吴苏冬，刘长利，王慧川，等. 参臼胶囊诱导肝癌SMMC7721细胞凋亡 [Ｊ]. 世界华人消化杂志， 2003； 11（7）∶908.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

ApoptosisInduction Effects of Octreotide on Human Gastric Cancer Cells

Abstract Full text Figures/Tables Video References Cited by

Format

Content